---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116782"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:01:14.937525+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eyenovia Q3 2024 net loss $7.9M; advances MicroPine Phase 3 and launches clobetasol

## Summary
- Net loss of $7.9M ($0.11/share) vs $7.3M ($0.18/share) in Q3 2023; SG&A up 27% to $3.7M.
- Cash & equivalents $7.2M at Sept 30, 2024; evaluating long-term financing options.
- Phase 3 CHAPERONE (MicroPine) interim analysis planned this quarter; myopia market >$3B annually.
- U.S. launch of clobetasol propionate 0.05% for post-surgical ocular inflammation/pain.
- Mydcombi shipped to 230 new offices since April; appointed Andrew Jones as CFO; raised $10.7M net.

## SEC filing metadata
- accession: 0001104659-24-116782
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465924116782/0001104659-24-116782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465924116782/tm2428070d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116782
- JSON: https://secwatch.observer/filing/0001104659-24-116782.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116782.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.